Surrozen, Inc./DE Revenue from Contract with Customer, Including Assessed Tax
Surrozen, Inc./DE (SRZN) reported Revenue from Contract with Customer, Including Assessed Tax of $5.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $5.00M, a 408.65% increase year-over-year.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $5.00M, a 408.65% increase year-over-year.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $528.00K, a 19.39% decline year-over-year.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $983.00K, a 90.17% decline year-over-year.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for fiscal 2025 was $3.48M, a 67.37% decline from fiscal 2024.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for fiscal 2024 was $10.65M.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Surrozen, Inc./DE revenue from contract with customer, including assessed tax for fiscal 2022 was $12.50M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00M 10-Q · filed 2026-08-06 | $10.00M 10-Q · filed 2026-08-06 | $10.53M derived: sum of 3 quarters · filed 2026-08-06 | $11.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-06 | $5.53M derived: sum of 2 quarters · filed 2026-05-06 | $6.51M derived: sum of 3 quarters · filed 2026-05-06 | $7.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.51M derived: sum of 2 quarters · filed 2026-03-23 | $2.49M derived: sum of 3 quarters · filed 2026-08-06 | $3.48M 10-K · filed 2026-03-23 |
| 2025-09-30 | $983.00K 10-Q · filed 2025-11-07 | $1.97M derived: sum of 2 quarters · filed 2026-08-06 | $2.95M 10-Q · filed 2025-11-07 | $3.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $983.00K 10-Q · filed 2026-08-06 | $1.97M 10-Q · filed 2026-08-06 | $2.62M derived: sum of 3 quarters · filed 2026-08-06 | $12.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $983.00K 10-Q · filed 2026-05-06 | $1.64M derived: sum of 2 quarters · filed 2026-05-06 | $11.64M derived: sum of 3 quarters · filed 2026-05-06 | $11.64M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $655.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.65M derived: sum of 2 quarters · filed 2026-03-23 | $10.65M derived: sum of 3 quarters · filed 2026-03-23 | $10.65M 10-K · filed 2026-03-23 |
| 2024-09-30 | $10.00M 10-Q · filed 2025-11-07 | $10.00M derived: sum of 2 quarters · filed 2025-11-07 | $10.00M 10-Q · filed 2025-11-07 | $10.00M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-08-08 | $0.00 derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $0.00 derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | $12.50M 10-K · filed 2024-04-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |